Tilsotolimod combo’s trial failure leaves refractory melanoma patients in limbo

Source: CLINICAL TRIALS ARENA, April 2021

Idera Pharmaceuticals has revealed that the Phase III, pivotal ILLUMINATE-301 trial of tilsotolimod in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) versus Yervoy alone in patients with anti-programmed death protein-1 (anti-PD-1)-refractory advanced melanoma did not meet its co-primary endpoint of objective response rate (ORR).

READ THE ORIGINAL FULL ARTICLE

 

Menu